Delivery Order SPE2DB25D9305-SPE2DB25FQAHS
- Not listed
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 capsules of Xtandi 40 mg with a ceiling value of $4,311.35. This firm fixed-price delivery order, issued on July 17, 2025, with an ultimate completion date of July 18, 2025, represents a single-line item fulfillment under the company's larger contract vehicle. The award carries no set-aside designation, allowing...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units). This firm fixed-price delivery order, issued on August 8, 2025, with an ultimate completion date of August 11, 2025, represents a discrete procurement action under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA. The award...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $4,169.59 by the Defense Logistics Agency on September 9, 2025, with an ultimate completion date of September 10, 2025. The delivery order covers 120 tablets of Xtandi 40 mg, an oncology medication used in the treatment of prostate cancer. This award was issued without a set-aside designation, allowing the vendor to compete...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units). The award, issued on August 29, 2025, with an ultimate completion date of September 2, 2025, utilizes a firm fixed-price contract type with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city....
- The Defense Logistics Agency awarded a delivery order valued at $8,622.72 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a time-sensitive pharmaceutical procurement fulfilling military healthcare supply requirements. The award...
- The Defense Logistics Agency awarded a $4,311.35 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The order, issued on July 23, 2025, with an ultimate completion date of July 24, 2025, carries no set-aside designation. Xtandi is a prescription oncology medication used in the treatment of prostate cancer, reflecting DMS Pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). The delivery order, issued on July 16, 2025, with an ultimate completion date of July 17, 2025, carries firm fixed-price terms and represents a direct procurement with no set-aside designation. This award falls under DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count units). This firm fixed-price delivery order, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a specific fulfillment under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. No...
- SPE2DB25D9305Indefinite Delivery Contract
- SPE2DB25D9305-SPE2DB25FQAHSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 120 tablets of Xtandi 40 mg. This delivery order was issued under a firm fixed-price contract type with an ultimate completion date of August 11, 2025, and no set-aside designation was used in the award. Xtandi is a prescription oncology medication used to treat prostate cancer, representing the type of specialized pharmaceutical products that DMS Pharmaceutical Group regularly supplies to federal healthcare facilities. This award is issued as a delivery order against DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency under the SPE2DB program, a $499.999 billion vehicle valid through November 2026 that enables DLA to procure a comprehensive range of pharmaceutical items to support military health facilities worldwide. DMS Pharmaceutical Group's federal contracting portfolio demonstrates consistent success in competing for pharmaceutical supply contracts with the Department of Defense without set-aside designations, leveraging its woman-owned small business status and established presence in the federal pharmaceutical supply chain since its SAM.gov registration in 2001.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 8/8/25 |